.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Moodys
Cerilliant
Federal Trade Commission
McKesson
Farmers Insurance
Argus Health
Johnson and Johnson
Deloitte
AstraZeneca

Generated: September 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title:Therapeutic compositions
Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.
Inventor(s): Brown; Marc Barry (Watford, GB), Crowthers; Michael Edward Donald (Hillsborough, GB), Nazir; Tahir (Isleworth, GB)
Assignee: LEO Laboratories Limited (Dublin, IE)
Application Number:13/563,698
Patent Claims: 1. A pharmaceutical formulation for topical use in treatment of a subject, said pharmaceutical formulation comprising ingenol angelate in an amount from about 0.001% to about 0.15% w/w, wherein at least about 95% of the ingenol angelate is ingenol-3-angelate (isoform `b`) and said pharmaceutical formulation has a pH of less than 4.

2. The pharmaceutical formulation of claim 1 having a pH of about 3.5 or less.

3. The pharmaceutical formulation of claim 1 having a pH of about 3.0.

4. The pharmaceutical formulation of claim 1 having a pH within the range of about 2.5 to less than 4.0.

5. The pharmaceutical formulation of claim 1, wherein said pharmaceutical formulation is a gel.

6. The pharmaceutical formulation of claim 1, wherein said pharmaceutical formulation is a cream.

7. The pharmaceutical formulation of claim 1, wherein said pharmaceutical formulation is an ointment.

8. The pharmaceutical formulation of claim 1, wherein said pharmaceutical formulation is a paint.

9. The pharmaceutical formulation of claim 1, wherein said pharmaceutical formulation is a lotion.

10. The pharmaceutical formulation of claim 1, wherein said pharmaceutical formulation is a foam.

11. The pharmaceutical formulation of claim 1, wherein said pharmaceutical formulation is a transdermal patch.

12. The pharmaceutical formulation of claim 1, wherein said pharmaceutical formulation is a sustained release formulation.

13. The pharmaceutical formulation of claim 1, wherein said pharmaceutical formulation is an emulsion.

14. The pharmaceutical formulation of claim 1, wherein said pharmaceutical formulation is an oil.

15. The pharmaceutical formulation of claim 1, wherein said pharmaceutical formulation is a buccal formulation.

16. The pharmaceutical formulation of claim 1, wherein said pharmaceutical formulation further comprises a penetration enhancer, a preservative, a gelling agent or a buffer.

17. A pharmaceutical formulation for topical use in treatment of a subject, said pharmaceutical formulation comprising ingenol-3-angelate (isoform `b`) and having a pH of less than 4, whereby, when an effective amount of said pharmaceutical formulation is applied to the skin, the rate of permeation of the ingenol-3-angelate (isoform `b`) across the skin is between about 11 ng cm.sup.-2h.sup.-1 and about 2 .mu.g cm.sup.-2h.sup.-1.

18. The pharmaceutical formulation of claim 17, wherein the rate of permeation of the ingenol-3-angelate (isoform `b`) across the skin is between about 11 ng cm.sup.-2h.sup.-1 and about 1 .mu.g cm.sup.-2h.sup.-1.

19. The pharmaceutical formulation of claim 18, wherein the amount of ingenol-3-angelate applied to the skin is between about 0.01 .mu.g cm.sup.-2 and 1000 .mu.g cm.sup.-2.

20. The pharmaceutical formulation of claim 18, wherein the amount of ingenol-3-angelate applied to the skin is between about 0.01 .mu.g cm.sup.-2 and 100 .mu.g cm.sup.-2.

21. The pharmaceutical formulation of claim 18 having a pH of about 3.5 or less.

22. The pharmaceutical formulation of claim 18 having a pH of about 3.0.

23. The pharmaceutical formulation of claim 18 having a pH within the range of about 2.5 to less than 4.0.

24. The pharmaceutical formulation of claim 18, wherein said pharmaceutical formulation is a gel.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Baxter
Colorcon
US Army
Novartis
Moodys
Chubb
McKesson
Cantor Fitzgerald
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot